[go: up one dir, main page]

ECSP13012678A - Antagonistas de mdm2 de espiro-oxindol - Google Patents

Antagonistas de mdm2 de espiro-oxindol

Info

Publication number
ECSP13012678A
ECSP13012678A ECSP13012678A ECSP13012678A EC SP13012678 A ECSP13012678 A EC SP13012678A EC SP13012678 A ECSP13012678 A EC SP13012678A EC SP13012678 A ECSP13012678 A EC SP13012678A
Authority
EC
Ecuador
Prior art keywords
espiro
oxindol
mdm2 antagonists
mdm2
antagonists
Prior art date
Application number
Other languages
English (en)
Inventor
Jean-Christophe Carry
Laurent Debussche
Shaomeng Wang
Wei Sun
Yujun Zhao
Sanjeev Kumar
Lance Leopold
Cedric Barriere
Kwame Amaning
Original Assignee
Univ Michigan
Ascenta Licensing Corp
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Michigan, Ascenta Licensing Corp, Sanofi Sa filed Critical Univ Michigan
Publication of ECSP13012678A publication Critical patent/ECSP13012678A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se proporcionan en la presente compuestos, composiciones y métodos en el campo de la química farmacéutica. Los compuestos y composiciones proporcionados en la presente se relacionan con espiro oxindoles que funcionan como antagonistas de la interacción entre p53 y MDM2 y su uso como agentes terapéuticos para el tratamiento de cáncer y otras enfermedades.
ECSP13012678 2010-11-12 2013-06-02 Antagonistas de mdm2 de espiro-oxindol ECSP13012678A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US41309410P 2010-11-12 2010-11-12
US201161451958P 2011-03-11 2011-03-11
US201161451968P 2011-03-11 2011-03-11
US201161470992P 2011-04-01 2011-04-01

Publications (1)

Publication Number Publication Date
ECSP13012678A true ECSP13012678A (es) 2013-08-30

Family

ID=46048358

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP13012678 ECSP13012678A (es) 2010-11-12 2013-06-02 Antagonistas de mdm2 de espiro-oxindol

Country Status (27)

Country Link
US (2) US8680132B2 (es)
EP (1) EP2638046A4 (es)
JP (1) JP2014500870A (es)
KR (1) KR101929188B1 (es)
CN (1) CN103298818B (es)
AR (1) AR083849A1 (es)
AU (1) AU2011326395B2 (es)
CA (1) CA2817585A1 (es)
CO (1) CO6721010A2 (es)
CR (1) CR20130271A (es)
DO (1) DOP2013000104A (es)
EA (1) EA201390682A1 (es)
EC (1) ECSP13012678A (es)
GT (1) GT201300118A (es)
IL (1) IL226275A0 (es)
MA (1) MA34732B1 (es)
MX (1) MX2013005238A (es)
NI (1) NI201300041A (es)
NZ (1) NZ611866A (es)
PE (1) PE20140408A1 (es)
PH (1) PH12013500955A1 (es)
SG (1) SG190230A1 (es)
TW (1) TWI535723B (es)
UA (1) UA109464C2 (es)
UY (1) UY33725A (es)
WO (1) WO2012065022A2 (es)
ZA (1) ZA201304042B (es)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG176463A1 (en) 2005-02-22 2011-12-29 Univ Michigan Small molecule inhibitors of mdm2 and uses thereof
DK2118123T3 (en) 2007-01-31 2016-01-25 Dana Farber Cancer Inst Inc Stabilized p53 peptides and uses thereof
EP3159352B1 (en) 2007-03-28 2023-08-02 President and Fellows of Harvard College Stitched polypeptides
EP2499145B1 (en) 2009-11-12 2016-01-27 The Regents Of The University Of Michigan Spiro-oxindole mdm2 antagonists
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
SI2603600T1 (sl) 2010-08-13 2019-04-30 Aileron Therapeutics, Inc. Peptidomimetični makrocikli
TWI494312B (zh) 2011-03-10 2015-08-01 Daiichi Sankyo Co Ltd 二螺吡咯啶衍生物
CN103717605B (zh) 2011-05-11 2016-05-18 密执安州立大学董事会 螺-羟吲哚mdm2拮抗剂
EP2768518A4 (en) 2011-10-18 2015-05-27 Aileron Therapeutics Inc PEPTIDOMIMETIC MACROCYCLES
US8927500B2 (en) 2012-02-15 2015-01-06 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
WO2013123267A1 (en) 2012-02-15 2013-08-22 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
US8993614B2 (en) 2012-03-15 2015-03-31 F. Hoffmann-La Roche Ag Substituted pyrrolidine-2-carboxamides
WO2013175417A1 (en) 2012-05-24 2013-11-28 Novartis Ag Pyrrolopyrrolidinone compounds
AU2013337388B2 (en) 2012-11-01 2018-08-02 Aileron Therapeutics, Inc. Disubstituted amino acids and methods of preparation and use thereof
KR102196882B1 (ko) 2012-12-20 2020-12-30 머크 샤프 앤드 돔 코포레이션 Hdm2 억제제로서의 치환된 이미다조피리딘
EP2752191A1 (en) * 2013-01-07 2014-07-09 Sanofi Compositions and methods using hdm2 antagonist and mek inhibitor
WO2014115080A1 (en) 2013-01-22 2014-07-31 Novartis Ag Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the p53/mdm2 interaction
WO2014115077A1 (en) 2013-01-22 2014-07-31 Novartis Ag Substituted purinone compounds
CN105209467B (zh) 2013-05-27 2018-06-08 诺华股份有限公司 咪唑并吡咯烷酮衍生物及其在治疗疾病中的用途
PL3004112T3 (pl) 2013-05-28 2018-02-28 Novartis Ag Pochodne pirazolo-pirolidyn-4-onu oraz ich zastosowanie w leczeniu choroby
CA2912986A1 (en) 2013-05-28 2014-12-04 Novartis Ag Pyrazolo-pyrrolidin-4-one derivatives as bet inhibitors and their use in the treatment of disease
AU2014351413B2 (en) 2013-11-21 2017-06-01 Novartis Ag Pyrrolopyrrolone derivatives and their use as BET inhibitors
SG11201606239UA (en) 2014-01-28 2016-08-30 Buck Inst For Res On Aging Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders
SG11201608667SA (en) 2014-04-17 2016-11-29 Univ Michigan Mdm2 inhibitors and therapeutic methods using the same
TW201613576A (en) * 2014-06-26 2016-04-16 Novartis Ag Intermittent dosing of MDM2 inhibitor
US10576064B2 (en) 2014-07-03 2020-03-03 Boehringer Ingelheim International Gmbh Spiro[3H-indole-3,2′-pyrrolidin]-2(1H)-one compounds and derivatives as MDM2-P53 inhibitors
WO2016028391A2 (en) 2014-08-18 2016-02-25 Hudson Biopharma Inc. Spiropyrrolidines as mdm2 inhibitors
PT3183254T (pt) 2014-08-21 2019-08-29 Boehringer Ingelheim Int Novos compostos de espiro[3h-indole-3,2¿-pirrolidin]-2(1h)-ona e derivados como inibidores de mdm2-p53
BR112017005736A2 (pt) 2014-09-24 2017-12-12 Aileron Therapeutics Inc macrociclos peptidomiméticos e formulações dos mesmos
MX2017003797A (es) 2014-09-24 2017-06-15 Aileron Therapeutics Inc Macrociclos peptidomimeticos y usos de los mismos.
CN107614003A (zh) 2015-03-20 2018-01-19 艾瑞朗医疗公司 拟肽大环化合物及其用途
CN108368161A (zh) 2015-09-10 2018-08-03 艾瑞朗医疗公司 作为mcl-1调节剂的拟肽大环化合物
SI3359542T1 (sl) 2015-10-09 2021-08-31 Boehringer Ingelheim International Gmbh Spojine in derivati spiro(3H-indol-3,2'-pirolidin)-2(1H)-ona kot MDM2-P53 inhibitorji
CN105693738A (zh) * 2016-01-14 2016-06-22 绍兴文理学院 3’-苯基螺[吲哚啉-3,2’-吡咯烷]-2-酮类衍生物及其制备方法和应用
JP7001614B2 (ja) 2016-04-06 2022-02-03 ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン リガンド依存性の標的タンパク質分解のための単官能性中間体
JP7037500B2 (ja) * 2016-04-06 2022-03-16 ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン Ｍｄｍ２タンパク質分解剤
ES2858151T3 (es) 2016-05-20 2021-09-29 Hoffmann La Roche Conjugados de PROTAC-anticuerpo y procedimientos de uso
CN107652296B (zh) * 2016-07-26 2020-08-04 南开大学 螺环氧化吲哚酰腙衍生物及其制备方法和在防治植物病毒、杀菌、杀虫方面的应用
JP6848047B2 (ja) 2016-08-08 2021-03-24 フェイ シアオ， スピロインドロンポリエチレングリコールカーボネート系化合物及びその組成物、調製方法及びその使用
RU2762573C2 (ru) 2016-11-15 2021-12-21 Новартис Аг Доза и режим введения для ингибиторов взаимодействия hdm2 с p53
US9822128B1 (en) 2017-06-01 2017-11-21 King Saud University Substituted spirooxindoles
BR112020013069A2 (pt) * 2017-12-29 2020-12-01 Gan & Lee Pharmaceuticals compostos capazes de serem usados como inibidor de tumor, método de preparação dos mesmos e aplicação dos mesmos
CN109988070B (zh) * 2017-12-29 2022-07-26 南京富润凯德生物医药有限公司 反式-1-羟基-1-(三氟甲基)-3-氨基环丁烷盐酸盐的中间体及制备方法和应用
EP3511334A1 (en) * 2018-01-16 2019-07-17 Adamed sp. z o.o. 1,2,3',5'-tetrahydro-2'h-spiro[indole-3,1'-pyrrolo[3,4-c]pyrrole]-2,3'-dione compounds as therapeutic agents activating tp53
US11046703B2 (en) 2018-10-08 2021-06-29 The Regents Of The University Of Michigan Small molecule MDM2 protein degraders
CA3171258A1 (en) 2020-03-19 2021-09-23 Nan JI Mdm2 degraders and uses thereof
CA3202764A1 (en) 2020-11-23 2022-05-27 Enanta Pharmaceuticals, Inc. Novel spiropyrrolidine derived antiviral agents
US20250073340A1 (en) * 2021-01-23 2025-03-06 Newave Pharmaceutical Inc. Spirocyclic mdm2 modulator and uses thereof
CN112876488B (zh) * 2021-02-18 2021-12-21 苏州大学 螺环吲哚啉衍生物及其制备方法和应用
JP2024511277A (ja) 2021-02-19 2024-03-13 メビオン・メディカル・システムズ・インコーポレーテッド 粒子線治療システムのためのガントリー
CN115215872A (zh) * 2021-04-15 2022-10-21 中国科学院上海药物研究所 具有取代苯基螺[吲哚啉-3,3′-吡咯烷]结构的小分子化合物
US11970502B2 (en) 2021-05-04 2024-04-30 Enanta Pharmaceuticals, Inc. Macrocyclic antiviral agents
US12398147B2 (en) 2021-05-11 2025-08-26 Enanta Pharmaceuticals, Inc. Macrocyclic spiropyrrolidine derived antiviral agents
US12479854B2 (en) 2021-07-29 2025-11-25 Enanta Pharmaceuticals, Inc. Spiropyrrolidine derived antiviral agents
WO2023056069A1 (en) 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same
US11912714B2 (en) 2021-11-12 2024-02-27 Enanta Pharmaceuticals, Inc. Spiropyrrolidine derived antiviral agents
WO2023086350A1 (en) * 2021-11-12 2023-05-19 Enanta Pharmaceuticals, Inc. Alkyne-containing antiviral agents
US11919910B2 (en) 2021-11-12 2024-03-05 Enanta Pharmaceuticals, Inc. Spiropyrrolidine derived antiviral agents
US12145941B2 (en) 2021-12-08 2024-11-19 Enanta Pharmaceuticals, Inc. Heterocyclic antiviral agents
WO2023107419A1 (en) 2021-12-08 2023-06-15 Enanta Pharmaceuticals, Inc. Saturated spirocyclics as antiviral agents
CN116283701B (zh) * 2021-12-21 2025-04-22 中国科学院上海药物研究所 具有4-(取代氨甲基)-5-新戊基-n-取代基吡咯烷-2-甲酰胺结构的化合物
WO2023196307A1 (en) 2022-04-05 2023-10-12 Enanta Pharmaceuticals, Inc. Novel spiropyrrolidine derived antiviral agents
WO2024078370A1 (zh) * 2022-10-13 2024-04-18 中国科学院上海药物研究所 具有取代苯基螺[吲哚啉-3,3'-吡咯烷]结构的小分子化合物
WO2024240858A1 (en) 2023-05-23 2024-11-28 Valerio Therapeutics Protac molecules directed against dna damage repair system and uses thereof

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3219661A (en) 1962-12-14 1965-11-23 Warner Lambert Pharmaceutical Spirooxindole and spirodehydroindole alkaloids and process therefor
GB1056537A (en) 1963-07-16 1967-01-25 Smith Kline French Lab Improvements in or relating to crystalline alkaloids of mitragyna citiata and compositions thereof
US3989816A (en) 1975-06-19 1976-11-02 Nelson Research & Development Company Vehicle composition containing 1-substituted azacycloheptan-2-ones
US4444762A (en) 1980-04-04 1984-04-24 Nelson Research & Development Company Vehicle composition containing 1-substituted azacyclopentan-2-ones
US6605712B1 (en) 1990-12-20 2003-08-12 Arch Development Corporation Gene transcription and ionizing radiation: methods and compositions
RU2084449C1 (ru) 1994-03-02 1997-07-20 Всероссийский научный центр по безопасности биологически активных веществ 1-бензил-2-оксотриптамин гидрохлорид и его производные, обладающие гепатозащитной активностью
US5773455A (en) 1996-06-28 1998-06-30 Biomeasure, Incorporated Inhibitors of prenyl transferases
US7083983B2 (en) 1996-07-05 2006-08-01 Cancer Research Campaign Technology Limited Inhibitors of the interaction between P53 and MDM2
EP0989856B1 (de) 1997-01-20 2010-05-12 IMMODAL PHARMAKA GESELLSCHAFT m.b.H. Verfahren und stoffe zur freisetzung eines wachstumsfaktors aus endothelzellen, und nach dem verfahren freigesetzter wachstumsfaktor sowie seine verwendung
EP1015430A4 (en) 1997-09-08 2001-01-17 Arqule Inc SPIRO (PRROLIDIN-2,3'-OXOINDOL) COMPOUNDS AND METHOD FOR USE THEREOF
AU5301499A (en) 1998-08-20 2000-03-14 Chugai Seiyaku Kabushiki Kaisha Method for screening candidate compounds for drug against tumor
US7205404B1 (en) 1999-03-05 2007-04-17 Metabasis Therapeutics, Inc. Phosphorus-containing prodrugs
US6831155B2 (en) 1999-12-08 2004-12-14 President And Fellows Of Harvard College Inhibition of p53 degradation
CN1182083C (zh) 2001-10-08 2004-12-29 廖宜芳 一种杀虫灭菌的配位肥及其制造方法
ES2301717T3 (es) 2001-12-18 2008-07-01 F. Hoffmann-La Roche Ag Cis-2,4,5-trifenil-imidazolinas y su utilizacion para el tratamiento de tumores.
ES2307822T3 (es) 2001-12-18 2008-12-01 F. Hoffmann-La Roche Ag Cis-imidazolinas como inhibidores de mdm2.
JP4023184B2 (ja) 2002-03-11 2007-12-19 昭和電工株式会社 発光体粒子及びその製造方法並びにその用途
WO2003106384A2 (en) 2002-06-01 2003-12-24 Johns Hopkins University Novel boronic chalcone derivatives and uses thereof
AU2003291269A1 (en) 2002-11-08 2004-06-03 Irm Llc Methods and compositions for modulating p53 transcription factor
US20050227932A1 (en) 2002-11-13 2005-10-13 Tianbao Lu Combinational therapy involving a small molecule inhibitor of the MDM2: p53 interaction
CA2514374A1 (en) 2003-02-13 2004-09-02 Government Of The United States Of America, As Represented By The Secret Ary, Department Of Health And Human Services Deazaflavin compounds and methods of use thereof
US6916833B2 (en) 2003-03-13 2005-07-12 Hoffmann-La Roche Inc. Substituted piperidines
US7132421B2 (en) 2003-06-17 2006-11-07 Hoffmann-La Roche Inc. CIS-imidazoles
US7425638B2 (en) 2003-06-17 2008-09-16 Hoffmann-La Roche Inc. Cis-imidazolines
US8173840B2 (en) 2003-07-29 2012-05-08 Signature R&D Holdings, Llc Compounds with high therapeutic index
US7589233B2 (en) 2003-07-29 2009-09-15 Signature R&D Holdings, Llc L-Threonine derivatives of high therapeutic index
KR20060073584A (ko) 2003-07-29 2006-06-28 시그너쳐 알 앤드 디 홀딩스, 엘엘씨 아미노산 프로드럭
WO2005063774A1 (en) 2003-12-22 2005-07-14 Johns Hopkins University Boronic acid aryl analogs
US8598127B2 (en) 2004-04-06 2013-12-03 Korea Research Institute Of Bioscience & Biotechnology Peptides for inhibiting MDM2 function
TWI350168B (en) 2004-05-07 2011-10-11 Incyte Corp Amido compounds and their use as pharmaceuticals
DE602005011132D1 (de) 2004-05-18 2009-01-02 Hoffmann La Roche Neuartige cis-imidazoline
GB0419481D0 (en) 2004-09-02 2004-10-06 Cancer Rec Tech Ltd Isoindolin-1-one derivatives
JP5156378B2 (ja) 2004-09-22 2013-03-06 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ＭＤＭ２とｐ５３の間の相互作用の阻害剤
CA2598690C (en) * 2005-02-22 2011-11-15 The Regents Of The University Of Michigan Small molecule inhibitors of mdm2 and uses thereof
SG176463A1 (en) 2005-02-22 2011-12-29 Univ Michigan Small molecule inhibitors of mdm2 and uses thereof
EP1891075B1 (en) 2005-05-24 2011-10-19 Merck Serono SA Tricyclic spiro derivatives as crth2 modulators
US7576082B2 (en) 2005-06-24 2009-08-18 Hoffman-La Roche Inc. Oxindole derivatives
US7495007B2 (en) 2006-03-13 2009-02-24 Hoffmann-La Roche Inc. Spiroindolinone derivatives
US8232298B2 (en) 2006-03-22 2012-07-31 Janssen Pharmaceutica N.V. Inhibitors of the interaction between MDM2 and P53
US8222288B2 (en) 2006-08-30 2012-07-17 The Regents Of The University Of Michigan Small molecule inhibitors of MDM2 and the uses thereof
US7737174B2 (en) 2006-08-30 2010-06-15 The Regents Of The University Of Michigan Indole inhibitors of MDM2 and the uses thereof
JP5399904B2 (ja) 2006-08-30 2014-01-29 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン Ｍｄｍ２の小分子阻害剤およびその使用
MX2009002735A (es) 2006-09-21 2009-05-08 Hoffmann La Roche Derivados de oxindol como agentes anticancerigenos.
US7638548B2 (en) 2006-11-09 2009-12-29 Hoffmann-La Roche Inc. Spiroindolinone derivatives
CN101605798A (zh) 2006-12-14 2009-12-16 第一三共株式会社 咪唑并噻唑衍生物
WO2008106507A2 (en) 2007-02-27 2008-09-04 University Of South Florida Mdm2/mdmx inhibitor peptide
WO2008119741A2 (en) 2007-03-29 2008-10-09 Novartis Ag 3-imidazolyl-indoles for the treatment of proliferative diseases
US7625895B2 (en) 2007-04-12 2009-12-01 Hoffmann-Le Roche Inc. Diphenyl-dihydro-imidazopyridinones
WO2008130614A2 (en) 2007-04-20 2008-10-30 University Of Pittsburg-Of The Commonwealth System Of Higher Education Selective and dual-action p53/mdm2/mdm4 antagonists
US7553833B2 (en) 2007-05-17 2009-06-30 Hoffmann-La Roche Inc. 3,3-spiroindolinone derivatives
US7834179B2 (en) 2007-05-23 2010-11-16 Hoffmann-La Roche Inc. Spiroindolinone derivatives
US8288377B2 (en) 2007-09-21 2012-10-16 Janssen Pharmaceutica N.V. Inhibitors of the interaction between MDM2 and p53
CZ301561B6 (cs) 2007-12-04 2010-04-14 Výzkumný ústav živocišné výroby, v. v. i. Prostredek pro prevenci a potlacování kokcidióz
US8134001B2 (en) 2007-12-14 2012-03-13 Hoffmann-La Roche Inc. Spiroindolinone derivatives
US7776875B2 (en) 2007-12-19 2010-08-17 Hoffman-La Roche Inc. Spiroindolinone derivatives
US7723372B2 (en) 2008-03-19 2010-05-25 Hoffman-La Roche Inc. Spiroindolinone derivatives
JPWO2009151069A1 (ja) 2008-06-12 2011-11-17 第一三共株式会社 ４，７−ジアザスピロ［２．５］オクタン環構造を有するイミダゾチアゾール誘導体
GB0811643D0 (en) 2008-06-25 2008-07-30 Cancer Rec Tech Ltd New therapeutic agents
US7928233B2 (en) 2009-02-10 2011-04-19 Hoffmann-La Roche Inc. Spiroindolinone pyridine derivatives
US8076482B2 (en) 2009-04-23 2011-12-13 Hoffmann-La Roche Inc. 3,3′-spiroindolinone derivatives
EP2499145B1 (en) * 2009-11-12 2016-01-27 The Regents Of The University Of Michigan Spiro-oxindole mdm2 antagonists
US8088815B2 (en) 2009-12-02 2012-01-03 Hoffman-La Roche Inc. Spiroindolinone pyrrolidines
US8288431B2 (en) 2010-02-17 2012-10-16 Hoffmann-La Roche Inc. Substituted spiroindolinones
WO2011106650A2 (en) 2010-02-27 2011-09-01 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Novel p53-mdm2/p53-mdm4 antagonists to treat proliferative disease
RU2012147597A (ru) * 2010-04-09 2014-05-20 Дзе Риджентс Оф Дзе Юниверсити Оф Мичиган Биомаркеры для ингибиторов mdm2, использующиеся для лечения заболевания
US8217044B2 (en) 2010-04-28 2012-07-10 Hoffmann-La Roche Inc. Spiroindolinone pyrrolidines
US20120046306A1 (en) 2010-08-18 2012-02-23 David Joseph Bartkovitz Substituted Heteroaryl Spiropyrrolidine MDM2 Antagonists
US20120071499A1 (en) 2010-09-20 2012-03-22 Xin-Jie Chu Substituted Spiro[3H-Indole-3,6'(5'H)-[1H]Pyrrolo[1,2c]Imidazole-1',2(1H,2'H)-diones
CN103717605B (zh) 2011-05-11 2016-05-18 密执安州立大学董事会 螺-羟吲哚mdm2拮抗剂

Also Published As

Publication number Publication date
KR20140027913A (ko) 2014-03-07
JP2014500870A (ja) 2014-01-16
UA109464C2 (uk) 2015-08-25
PH12013500955A1 (en) 2015-11-06
EP2638046A2 (en) 2013-09-18
US20140148494A1 (en) 2014-05-29
AU2011326395B2 (en) 2016-01-07
US20120122947A1 (en) 2012-05-17
TW201305177A (zh) 2013-02-01
EP2638046A4 (en) 2014-06-25
US9302120B2 (en) 2016-04-05
WO2012065022A3 (en) 2012-10-04
MA34732B1 (fr) 2013-12-03
UY33725A (es) 2012-06-29
CN103298818A (zh) 2013-09-11
CN103298818B (zh) 2016-06-29
NI201300041A (es) 2013-12-17
CO6721010A2 (es) 2013-07-31
NZ611866A (en) 2015-04-24
ZA201304042B (en) 2014-02-26
PE20140408A1 (es) 2014-04-10
CA2817585A1 (en) 2012-05-18
MX2013005238A (es) 2013-09-02
TWI535723B (zh) 2016-06-01
US8680132B2 (en) 2014-03-25
DOP2013000104A (es) 2013-10-15
GT201300118A (es) 2014-08-05
KR101929188B1 (ko) 2018-12-17
IL226275A0 (en) 2013-07-31
CR20130271A (es) 2013-10-03
EA201390682A1 (ru) 2014-01-30
AR083849A1 (es) 2013-03-27
SG190230A1 (en) 2013-06-28
AU2011326395A1 (en) 2013-05-09
WO2012065022A2 (en) 2012-05-18

Similar Documents

Publication Publication Date Title
ECSP13012678A (es) Antagonistas de mdm2 de espiro-oxindol
CO6501131A2 (es) Antagonistas de espiro-oxindol de mdm2
MX346375B (es) Antagonistas de espiro-oxindol de mdm2.
CL2014001752A1 (es) Compuestos biciclicos sustituidos; composicion farmaceutica que los comprende; y uso en el tratamiento de enfermedades tales como cancer, alzheimer, sida, entre otras.
NI201500067A (es) Compuestos de pirrolopirimidina como inhibidores de quinasa
CO6680708A2 (es) Compuesto modulares de estrógenos y composiciones que comprenden los mismos
MX2020003532A (es) Tetrahidro-pirido[3,4-b]indoles moduladores de receptores de estrogenos y usos de los mismos.
CL2016001629A1 (es) Compuestos tricíclicos como agentes anticancerígenos
CU20150163A7 (es) DERIVADOS DE 5-HETEROARIL-4-FENIL-4,5-DIHIDROPIRROLO(3,4-c)PIRAZOL-6-ONA ACTIVOS COMO INHIBIDORES DE BET
CL2012002189A1 (es) Compuestos derivados de pirrolidina-2-carboxamidas sustituidas; inhibidores de la interaccion mdm2-p53; composicion farmaceutica; y su uso para el tratamiento del cancer, en particular de tumores solidos.
AR088694A1 (es) Peptidos citotoxicos y conjugados de anticuerpo-farmaco de los mismos
CL2013000018A1 (es) Compuestos derivados de indolizina , su procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento del cancer, entre otros.
NI201500059A (es) Inhibidores de la tirosina-quinasa de bruton
GT201200334A (es) Morfolinopirimidinas y su uso en terapia
GT201200321A (es) Derivados de heteroaril imidazolona como inhibidores de jak
GT201400142A (es) Nuevos derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
AR091837A1 (es) Compuestos para inmunoterapia dirigida
UY34220A (es) Indazoles, composiciones farmacéuticas y uso de los mismos
NI201100082A (es) Compuestos de isoindolina para uso en el tratamiento de cáncer.
CL2014001865A1 (es) Compuestos derivados de fosfatos; procedimiento de preparacion; composiciones farmaceuticas que los contienen y uso en el tratamiento del cancer.
GT201500069A (es) Piridinonas bicìclicas novedosas
UY34356A (es) Derivados de estra-1,3,5(10),16-tetraen-3-carboxamida, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos
GT201500143A (es) Composiciones que comprenden vortioxetina y donepezilo campo tecnico
ECSP13012988A (es) Derivados de tienopirimidina (2,3-d) y su uso para tratar arritmia
CU20100248A7 (es) Compuestos de piridina